Novartis’s QVA149 indacaterol maleate/glycopyrronium DPI demonstrated 15% greater reduction in all COPD exacerbations compared to glycopyrronium and 14% compared to tiotropium according to study results published April 23 2013 in Lancet Respiratory Medicine. QVA149 reduced moderate-to-severe exacerbations by 12% over glycopyrronium. The study also showed improved lung function and quality of life for patients using QVA149.
The SPARK study, which involved over 2,200 patients with severe to very severe COPD, was primarily designed to show the superiority of QVA149 versus glycopyrronium monotherapy. The study is one of ten in the IGNITE Phase 3 clinical program.
Novartis Pharma Global Head of Development Tim Wright commented, “We are delighted that results from SPARK demonstrated that QVA149 reduced the overall rate of exacerbations in patients with severe and very severe COPD. For physicians and their patients, these findings offer hope of a new effective treatment to prevent debilitating COPD exacerbations and improve health-related quality of life.”
Read the Novartis press release.
Read the Lancet Respiratory Medicine article.
